EndoForum Live 2027 Brings Special Interest Group Programming Into One Virtual Day
The Endocrine Society is consolidating some of its most active Special Interest Group programming into a single virtual event, giving members a concentrated day of discussion across several high-interest endocrine topics. EndoForum Live 2027 is scheduled for January 23, 2027, from 9:00 AM to 2:00 PM ET and will be offered free to members.
The format matters because the Society’s SIGs have already become a steady source of professional exchange. These groups connect clinicians and researchers around shared disease areas, and the move to a full-day integrated program reflects how strongly that model has resonated with endocrinologists seeking practical dialogue rather than passive listening. The event is designed to be interactive, with opportunities for questions, discussion, and continued engagement after the live sessions end.
The agenda is not a broad generalist sweep. It is a deliberately clinical lineup built around areas that shape day-to-day endocrine care: low-risk thyroid cancer, primary hyperparathyroidism, diabetes management across hormonal transitions, difficult Cushing syndrome cases, and practical use of artificial intelligence in endocrinology.
Low-risk thyroid cancer remains a field where surveillance, risk stratification, and avoidance of overtreatment all compete for attention. In endocrine practice, the challenge is often not identifying cancer, but deciding when aggressive intervention is unnecessary and when careful monitoring preserves quality of life without compromising oncologic safety.
Thyroid Cancer, Parathyroid Disease, and the Need for Precision
One planned session focuses on low-risk thyroid cancer, a topic that continues to pull endocrine oncologists, surgeons, and general endocrinologists toward the same question: how can care stay appropriately measured without drifting into therapeutic inertia? In contemporary practice, the shift toward selective intervention has forced clinicians to weigh tumor biology, patient preference, and the burden of lifelong follow-up in a more nuanced way.
Another session will examine primary hyperparathyroidism beyond serum calcium, with an emphasis on skeletal heterogeneity and precision medicine. The framing is clinically important. Calcium values alone do not fully capture the skeletal consequences of disordered parathyroid hormone excess, and bone involvement can differ substantially from patient to patient even when routine laboratory patterns look similar. A session built around skeletal heterogeneity signals a more granular approach to fracture risk, imaging interpretation, and individualized treatment decisions.
The practical consequence is straightforward: endocrine disorders that once seemed defined by single laboratory abnormalities are increasingly managed as systems diseases, with downstream effects on bone, kidney, metabolism, and long-term function.
Diabetes Care Across Puberty and Menopause
The diabetes session, titled From Puberty to Menopause: Glycemic Management Across Hormonal Transitions in Girls and Women with Diabetes, places hormonal biology at the center of glucose management. Puberty, menstrual cycling, pregnancy-related physiology, and menopause each alter insulin sensitivity, energy balance, and glycemic variability in ways that can complicate treatment plans built on stable assumptions.
For clinicians, these transitions often explain why apparently appropriate regimens fail at predictable times. Adolescents can experience worsening insulin resistance as sex steroids rise, while adult women may see glycemic shifts tied to reproductive stage, menopausal transition, or changes in body composition. A session that traces those phases together gives members a chance to rethink diabetes care as a moving target rather than a fixed protocol.
This is the kind of conversation that translates directly to patient care. A treatment plan that ignores endocrine transition states can look adequate on paper and still miss the physiology driving persistent hyperglycemia.
Difficult Cushing Cases and the Limits of Routine Testing
Among the most clinically charged sessions is When Cortisol Testing Doesn’t Make Sense: Solving the Difficult Cushing Case. Cushing syndrome sits at the intersection of endocrine suspicion and diagnostic frustration, where symptoms can be protean and screening tests are vulnerable to false positives, false negatives, and confusion from overlapping conditions.
A session built around difficult cases acknowledges a common reality in endocrine practice: the algorithm works best when the phenotype is clean. Real patients are more complicated. Obesity, depression, sleep disturbance, glucocorticoid exposure, and cyclic or mild disease can make the usual testing sequence less decisive, forcing clinicians to revisit pretest probability and the logic of each assay.
The value of this kind of discussion is in calibration. Endocrinologists do not need more testing theory alone; they need expert reasoning about when cortisol measurements clarify the diagnosis and when they obscure it.
Artificial intelligence enters the program as a practical tool rather than a slogan. A session on Practical Application of AI in Endocrinology suggests a focus on current workflow, clinical decision support, and realistic use cases rather than abstract speculation. In a specialty that generates large volumes of longitudinal data, imaging interpretation, and laboratory trend review, AI tools could eventually assist with triage, pattern recognition, and documentation support — but the clinical boundary conditions matter just as much as the promise.
Member Engagement as a Clinical Resource
EndoForum Live also reflects a broader shift in how endocrine education is being delivered. Traditional webinars ask clinicians to listen; this event is built to make them participate. That difference is meaningful because endocrine practice often advances through case discussion, uncertainty management, and exchange between subspecialists who may be working on very different pieces of the same disease process.
All discussions and resources from the event will remain available within EndoForum after the live program ends, extending the educational value beyond the January session. That archived access matters for a field where members often need to revisit content after clinic, tumor board, or conference schedules have passed.
Capacity constraints mean the 2027 event will not include programming from every SIG. Future iterations are expected to broaden the scope, which leaves room for additional endocrine subspecialties to enter the format. For now, the inaugural event serves as a concentrated snapshot of where member interest is strongest and where practical endocrine discussion is most likely to influence day-to-day care.
The real test will be whether this compressed model can preserve the range and depth that have made the individual SIGs so popular. If it does, EndoForum Live could become a durable way to connect endocrine education with the realities of clinical practice, from diagnostic ambiguity to therapeutic precision.